{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:08:31Z","timestamp":1784408911212,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"DOI":"10.7759\/cureus.86874","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T18:54:21Z","timestamp":1751050461000},"source":"Crossref","is-referenced-by-count":1,"title":["Early Myasthenia Gravis Activities of Daily Living (MG-ADL) Response to Ravulizumab in Acetylcholine Receptor-Positive Generalized Myasthenia Gravis Refractory: A Case Report From Latin America"],"prefix":"10.7759","author":[{"given":"Manuel","family":"Orellana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus NE","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016, 375:2570-81. 10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment","volume":"31","author":"Gilhus NE","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, et al.. Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol. 2024, 31:e16229. 10.1111\/ene.16229","journal-title":"Eur J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis K","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020, 11:596981. 10.3389\/fneur.2020.596981","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga AR","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM, et al.. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022, 21:176-88. 10.1016\/S1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami P","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al.. International Consensus Guidance for Management of Myasthenia Gravis: 2020 update. Neurology. 2021, 96:114-22. 10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza R","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018, 11:0. 10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio R","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024, 20:84-98. 10.1038\/s41582-023-00916-w","journal-title":"Nat Rev Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan D","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, et al.. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018, 13:e0195909. 10.1371\/journal.pone.0195909","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee JW","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al.. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019, 133:530-9. 10.1182\/blood-2018-09-876136","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01481-6","article-title":"Ravulizumab: a review in atypical haemolytic uraemic syndrome","volume":"81","author":"Syed YY","year":"2021","unstructured":"Syed YY. Ravulizumab: a review in atypical haemolytic uraemic syndrome. Drugs. 2021, 81:587-94. 10.1007\/s40265-021-01481-6","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu T","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et al.. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022, 1:0. 10.1056\/EVIDoa2100066","journal-title":"NEJM Evid"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.648","article-title":"506VP Long-term efficacy and safety of ravulizumab in adults with AChR-Ab+ gMG: final results from the phase 3 CHAMPION MG open-label extension","volume":"43","author":"Vu T","year":"2024","unstructured":"Vu T, Mantegazza R, Annane D, et al.. 506VP Long-term efficacy and safety of ravulizumab in adults with AChR-Ab+ gMG: final results from the phase 3 CHAMPION MG open-label extension. Neuromuscul Disord. 2024, 43:104441. 10.1016\/j.nmd.2024.07.648","journal-title":"Neuromuscul Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab465","article-title":"Next-generation antibody-based therapies in neurology","volume":"145","author":"Ruck T","year":"2022","unstructured":"Ruck T, Nimmerjahn F, Wiendl H, L\u00fcnemann JD. Next-generation antibody-based therapies in neurology. Brain. 2022, 145:1229-41. 10.1093\/brain\/awab465","journal-title":"Brain"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe GI","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999, 52:1487-9. 10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi S","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011, 44:727-31. 10.1002\/mus.22140","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16490","article-title":"Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"31","author":"Habib AA","year":"2024","unstructured":"Habib AA, Benatar M, Vu T, et al.. Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Eur J Neurol. 2024, 31:e16490. 10.1111\/ene.16490","journal-title":"Eur J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12234-2","article-title":"Ravulizumab in myasthenic crisis: the first case report","volume":"271","author":"Konen FF","year":"2024","unstructured":"Konen FF, Jendretzky KF, Ratuszny D, et al.. Ravulizumab in myasthenic crisis: the first case report. J Neurol. 2024, 271:2898-901. 10.1007\/s00415-024-12234-2","journal-title":"J Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383544-early-myasthenia-gravis-activities-of-daily-living-mg-adl-response-to-ravulizumab-in-acetylcholine-receptor-positive-generalized-myasthenia-gravis-refractory-a-case-report-from-latin-america","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T18:54:22Z","timestamp":1751050462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383544-early-myasthenia-gravis-activities-of-daily-living-mg-adl-response-to-ravulizumab-in-acetylcholine-receptor-positive-generalized-myasthenia-gravis-refractory-a-case-report-from-latin-america"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.86874","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}